EDP Sciences logo
Subscriber Authentication Point
Search
Menu
Home All issues Volume 37 / No 8-9 (Août–Septembre 2021) Med Sci (Paris), 37 8-9 (2021) 807-811 References
Issue
Med Sci (Paris)
Volume 37, Number 8-9, Août–Septembre 2021
Nos jeunes pousses ont du talent !
Page(s) 807 - 811
Section Partenariat médecine/sciences - Écoles doctorales - Masters
DOI https://doi.org/10.1051/medsci/2021125
Published online 07 September 2021
  1. World Health Organization World malaria report 2019, Sl 2019 ; Geneva WHO [Google Scholar]
  2. World Health Organization Stratégie technique mondiale de lutte contre le paludisme 2016–2030 2015 ; Geneva WHO [Google Scholar]
  3. RTS.S Clinical trials partnership. efficacy and safety of RTS, S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. Lancet 2015; 386 : 31–45. [CrossRef] [PubMed] [Google Scholar]
  4. Cockburn IA Seder RA Malaria prevention: from immunological concepts to effective vaccines and protective antibodies. Nat Immunol 2018 ; 19 : 1199–1211. [CrossRef] [PubMed] [Google Scholar]
  5. Cohen J Nussenzweig V Vekemans J et al. From the circumsporozoite protein to the RTS. S/AS candidate vaccine. Human Vaccines 2010 ; 6 : 90–96. [Google Scholar]
  6. Sinnis P Nardin E Sporozoite antigens: biology and immunology of the circumsporozoite protein and thrombospondin-related anonymous protein. Chem Immunol 2002 ;70–96. [CrossRef] [PubMed] [Google Scholar]
  7. Kisalu NK Idris AH Weidle C et al. A human monoclonal antibody prevents malaria infection by targeting a new site of vulnerability on the parasite. Nat Med 2018 ; 24 : 408–416. [CrossRef] [PubMed] [Google Scholar]
  8. Murugan R, Scally SW, Costa G, et al. Evolution of protective human antibodies against Plasmodium falciparum circumsporozoite protein repeat motifs. Nat Med 2020; 26 : 1135–45. [CrossRef] [PubMed] [Google Scholar]
  9. Wang LT, Pereira LS, Flores-Garcia Y, et al. A Potent anti-malarial human monoclonal antibody targets circumsporozoite protein minor repeats and neutralizes sporozoites in the liver. Immunity 2020; 53 : 733–44. [CrossRef] [PubMed] [Google Scholar]
  10. Vaughan AM Mikolajczak SA Wilson EM et al. Complete Plasmodium falciparum liver-stage development in liver-chimeric mice. J Clin Invest 2012 ; 122 : 3618–3628. [PubMed] [Google Scholar]
  11. Oyen D Torres JL Wille-Reece U et al. Structural basis for antibody recognition of the NANP repeats in Plasmodium falciparum circumsporozoite protein. Proc Natl Acad Sci USA 2017 ; 114 : 10438–10445. [Google Scholar]
  12. Tan J Sack BK Oyen D et al. A public antibody lineage that potently inhibits malaria infection through dual binding to the circumsporozoite protein. Nat Med 2018 ; 24 : 401–407. [PubMed] [Google Scholar]
  13. Imkeller K Scally SW Bosch A et al. Antihomotypic affinity maturation improves human B cell responses against a repetitive epitope. Science 2018 ; 360 : 1358–1362. [PubMed] [Google Scholar]
  14. Yang ASP O’Neill MT Jennison C et al. Cell traversal activity is important for plasmodium falciparum liver infection in humanized mice. Cell Rep 2017 ; 18 : 3105–3116. [PubMed] [Google Scholar]
  15. Aliprandini E Tavares J Panatieri RH et al. Cytotoxic anti-circumsporozoite antibodies target malaria sporozoites in the host skin. Nat Microbiol 2018 ; 3 : 1224–1233. [PubMed] [Google Scholar]
  16. Burton DR Hangartner L Broadly neutralizing antibodies to hiv and their role in vaccine design. Annu Rev Immunol 2016 ; 34 : 635–659. [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.